{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:17:13Z","timestamp":1791472633252,"version":"4.3.4"},"reference-count":111,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2006961"],"award-info":[{"award-number":["NRF-2021R1A2C2006961"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1A5A2017476"],"award-info":[{"award-number":["NRF-2020R1A5A2017476"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Influenza infection is serious and debilitating for humans and animals. The influenza virus undergoes incessant mutation, segment recombination, and genome reassortment. As a result, new epidemics and pandemics are expected to emerge, making the elimination challenging of the disease. Antiviral therapy has been used for the treatment of influenza since the development of amantadine in the 1960s; however, its use is hampered by the emergence of novel strains and the development of drug resistance. Thus, combinational therapy with two or more antivirals or immunomodulators with different modes of action is the optimal strategy for the effective treatment of influenza infection. In this review, we describe current options for combination therapy, their performance, and constraints imposed by resistance, calling attention to the advantages of combination therapy against severe influenza infections. We also discuss the challenges of influenza therapy and the limitations of approved antiviral drugs.<\/jats:p>","DOI":"10.3390\/microorganisms11010183","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T02:28:44Z","timestamp":1673490524000},"page":"183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy"],"prefix":"10.3390","volume":"11","author":[{"given":"Sania","family":"Batool","sequence":"first","affiliation":[{"name":"Department of Microbiology, Chungbuk National University, College of Medicine and Medical Research Institute, Cheongju 28644, Chungbuk, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Chokkakula","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Chungbuk National University, College of Medicine and Medical Research Institute, Cheongju 28644, Chungbuk, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6073-0783","authenticated-orcid":false,"given":"Min-Suk","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Chungbuk National University, College of Medicine and Medical Research Institute, Cheongju 28644, Chungbuk, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco, S., and Gomez, J. (2013). New World Bats Harbor Diverse Influenza A Viruses. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003657"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Richard, M., Erny, A., Car\u00e9, B., Traversier, A., Barthelemy, M., Hay, A., Lin, Y.P., Ferraris, O., and Lina, B. (2012). Rescue of a H3N2 Influenza Virus Containing a Deficient Neuraminidase Protein by a Hemagglutinin with a Low Receptor-Binding Affinity. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033880"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/978-981-10-8456-0_5","article-title":"Structure and Function of Influenza Virus Ribonucleoprotein","volume":"88","author":"Lo","year":"2018","journal-title":"Virus Protein Nucl. Complexes"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/rmv.666","article-title":"Structure of influenza virus ribonucleoprotein complexes and their packaging into virions","volume":"20","author":"Noda","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev-virology-010320-070410","article-title":"Post-Translation Regulation of Influenza Virus Replication","volume":"7","author":"Dawson","year":"2020","journal-title":"Annu. Rev. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.virol.2010.12.003","article-title":"Influenza virus assembly and budding","volume":"411","author":"Rossman","year":"2011","journal-title":"Virology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1345\/aph.10118","article-title":"Neuraminidase Inhibitors: Zanamivir and Oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"ref_8","unstructured":"(2022, June 12). Distribution of Amantadine-Resistant H5N1 Avian Influenza Variants in Asia\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/16703504\/."},{"key":"ref_9","unstructured":"(2022, June 12). Efficacy and Safety of Low Dosage Amantadine Hydrochloride as Prophylaxis for Influenza A\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/2712549\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.144.3620.862","article-title":"Antiviral Activity of 1-Adamantanamine (Amantadine)","volume":"144","author":"Davies","year":"1964","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2013.03.014","article-title":"Influenza virus resistance to neuraminidase inhibitors","volume":"98","author":"Samson","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/363418a0","article-title":"Rational Design of Potent Sialidase-Based Inhibitors of Influenza Virus Replication","volume":"363","author":"Wu","year":"1993","journal-title":"Nature"},{"key":"ref_13","first-page":"447","article-title":"Zanamivir (Glaxo Wellcome)","volume":"3","author":"Oxford","year":"2000","journal-title":"IDrugs"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00003495-199958040-00016","article-title":"Zanamivir","volume":"58","author":"Dunn","year":"1999","journal-title":"Drugs"},{"key":"ref_15","unstructured":"(2022, June 13). Annex: Summary of Product Characteristics\u2014Google Scholar. Available online: https:\/\/scholar.google.com\/scholar_lookup?journal=Tamiflu+Summary+of+Product+Characteristics&."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00003088-199937060-00003","article-title":"Clinical Pharmacokinetics of the Prodrug Oseltamivir and Its Active Metabolite Ro 64-0802","volume":"37","author":"He","year":"1999","journal-title":"Clin. Pharmacokinet."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase Inhibitors for Influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_18","unstructured":"Roberts, N.A., Wiltshire, H.R., Mendel, D.B., and Webster, R.G. (, January March). Oseltamivir carboxylate is effective against all subtypes of influenza neuraminidase, poster 135. Proceedings of the 3rd Annual ASM Biodefense Research Meeting American Society for Microbiology, Washington, DC, USA."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ii5","DOI":"10.1093\/jac\/dkq015","article-title":"Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations","volume":"65","author":"Davies","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/cid\/cis352","article-title":"Peramivir Use for Treatment of Hospitalized Patients with Influenza A(H1N1)pdm09 Under Emergency Use Authorization, October 2009\u2013June 2010","volume":"55","author":"Yu","year":"2012","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cis351","article-title":"Emergency Use Authorization for Intravenous Peramivir: Evaluation of Safety in the Treatment of Hospitalized Patients Infected with 2009 H1N1 Influenza A Virus","volume":"55","author":"Sorbello","year":"2012","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/00498250903447691","article-title":"Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats","volume":"40","author":"Koyama","year":"2010","journal-title":"Xenobiotica Fate Foreign Compd. Biol. Syst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1586\/eri.11.112","article-title":"Laninamivir octanoate: A new long-acting neuraminidase inhibitor for the treatment of influenza","volume":"9","author":"Ikematsu","year":"2011","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/095632020301400502","article-title":"In Vitro and in Vivo Activities of T-705 and Oseltamivir against Influenza Virus","volume":"14","author":"Takahashi","year":"2003","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_25","unstructured":"(2022, June 13). T-705 (Favipiravir) Suppresses Tumor Necrosis Factor \u03b1 Production in Response to Influenza Virus Infection: A Beneficial Feature of T-705 as an Anti-Influenza Drug\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/28105854\/."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"LB16 (2022, June 13). Phase 3 Trial of Baloxavir Marboxil in High-Risk Influenza Patients (CAPSTONE-2 Study) |Open Forum Infectious Diseases|Oxford Academic. Available online: https:\/\/academic.oup.com\/ofid\/article\/5\/suppl_1\/S764\/5206266.","DOI":"10.1093\/ofid\/ofy229.2190"},{"key":"ref_29","first-page":"395","article-title":"Occurrence of amantadine- and rimantadine-resistant influenza A virus strains during the 1980 epidemic","volume":"25","author":"Heider","year":"1981","journal-title":"Acta Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJM198912213212502","article-title":"Emergence and Apparent Transmission of Rimantadine-Resistant Influenza A Virus in Families","volume":"321","author":"Hayden","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/314994","article-title":"Low Incidence of Rimantadine Resistance in Field Isolates of Influenza A Viruses","volume":"180","author":"Ziegler","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(05)67338-2","article-title":"Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern","volume":"366","author":"Bright","year":"2005","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Dong, G., Peng, C., Luo, J., Wang, C., Han, L., Wu, B., Ji, G., and He, H. (2015). Adamantane-Resistant Influenza A Viruses in the World (1902\u20132013): Frequency and Distribution of M2 Gene Mutations. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119115"},{"key":"ref_34","unstructured":"CDC (2022, June 14). \u2018Influenza Antiviral Medications: Clinician Summary\u2019, Centers for Disease Control and Prevention, Available online: https:\/\/www.cdc.gov\/flu\/professionals\/antivirals\/summary-clinicians.htm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2018.1540586","article-title":"Animal models used to assess influenza antivirals","volume":"13","author":"Mifsud","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/ppul.10320","article-title":"Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model","volume":"36","author":"Ottolini","year":"2003","journal-title":"Pediatr. Pulmonol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1128\/AAC.00793-15","article-title":"Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates","volume":"59","author":"Itoh","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00412-11","article-title":"Efficacy of Single Intravenous Injection of Peramivir against Influenza B Virus Infection in Ferrets and Cynomolgus Macaques","volume":"55","author":"Kitano","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1128\/AAC.02817-14","article-title":"Efficacy of Repeated Intravenous Administration of Peramivir against Highly Pathogenic Avian Influenza A (H5N1) Virus in Cynomolgus Macaques","volume":"58","author":"Kitano","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.antiviral.2008.06.014","article-title":"Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques","volume":"80","author":"Stittelaar","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann. Appl. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2165\/00002018-200528120-00007","article-title":"Clinical Relevance of Drug-Drug Interactions: A structured assessment procedure","volume":"28","author":"Flikweert","year":"2005","journal-title":"Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","article-title":"Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives","volume":"12","author":"Hurt","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4065\/79.4.523","article-title":"Avian Influenza: A New Pandemic Threat?","volume":"79","author":"Trampuz","year":"2004","journal-title":"Mayo Clin. Proc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/molbev\/mst204","article-title":"Comparative Dynamics and Distribution of Influenza Drug Resistance Acquisition to Protein M2 and Neuraminidase Inhibitors","volume":"31","author":"Garcia","year":"2014","journal-title":"Mol. Biol. Evol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team (2009). Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in Humans. N. Engl. J. Med., 360, 2605\u20132615.","DOI":"10.1056\/NEJMoa0903810"},{"key":"ref_47","first-page":"304","article-title":"Avian influenza A (H7N9) virus infection in humans: Epidemiology, evolution, and pathogenesis","volume":"28","author":"Husain","year":"2014","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/irv.12047","article-title":"Influenza neuraminidase inhibitors: Antiviral action and mechanisms of resistance","volume":"7","year":"2013","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.vaccine.2009.07.017","article-title":"Structural basis for oseltamivir resistance of influenza viruses","volume":"27","author":"Collins","year":"2009","journal-title":"Vaccine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature05114","article-title":"The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design","volume":"443","author":"Russell","year":"2006","journal-title":"Nature"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"10693","DOI":"10.1128\/JVI.01703-16","article-title":"Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor","volume":"90","author":"Wu","year":"2016","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0166-3542(01)00215-7","article-title":"Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo","volume":"54","author":"Carr","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/nature06956","article-title":"Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants","volume":"453","author":"Collins","year":"2008","journal-title":"Nature"},{"key":"ref_54","unstructured":"(2022, June 15). Effect of Neuraminidase Inhibitor\u2013Resistant Mutations on Pathogenicity of Clade 2.2 A\/Turkey\/15\/06 (H5N1) Influenza Virus in Ferrets|PLOS Pathogens. Available online: https:\/\/journals.plos.org\/plospathogens\/article?id=10.1371\/journal.ppat.1000933."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00316-11","article-title":"Novel Genotyping and Quantitative Analysis of Neuraminidase Inhibitor Resistance-Associated Mutations in Influenza A Viruses by Single-Nucleotide Polymorphism Analysis","volume":"55","author":"Duan","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1586\/14787210.4.5.795","article-title":"Resistance to anti-influenza drugs: Adamantanes and neuraminidase inhibitors","volume":"4","author":"Hurt","year":"2006","journal-title":"Expert Rev. Anti-infect. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: The epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/irv.12187","article-title":"Peramivir and laninamivir susceptibility of circulating influenza A and B viruses","volume":"8","author":"Leang","year":"2013","journal-title":"Influ. Other Respir. Viruses"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.antiviral.2014.07.001","article-title":"Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012\u20132013","volume":"110","author":"Meijer","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_60","first-page":"20666","article-title":"A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013","volume":"19","author":"Takashita","year":"2014","journal-title":"Euro Surveill. Bull. Eur. Sur Mal. Transm. Eur. Commun. Dis. Bull."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/infdis\/jiq010","article-title":"Generation and Characterization of Recombinant Pandemic Influenza A(H1N1) Viruses Resistant to Neuraminidase Inhibitors","volume":"203","author":"Pizzorno","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/AAC.02269-12","article-title":"Evaluation of Recombinant 2009 Pandemic Influenza A (H1N1) Viruses Harboring Zanamivir Resistance Mutations in Mice and Ferrets","volume":"57","author":"Pizzorno","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1128\/AAC.03313-14","article-title":"Characterization of Drug-Resistant Influenza Virus A(H1N1) and A(H3N2) Variants Selected In Vitro with Laninamivir","volume":"58","author":"Samson","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00301","DOI":"10.1128\/AAC.00301-20","article-title":"Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone","volume":"64","author":"Adams","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11613","DOI":"10.1073\/pnas.1811345115","article-title":"The mechanism of resistance to favipiravir in influenza","volume":"115","author":"Goldhill","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1001\/jama.2009.294","article-title":"Infections with Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States","volume":"301","author":"Dharan","year":"2009","journal-title":"JAMA"},{"key":"ref_67","unstructured":"(2022, June 16). Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice|Antimicrobial Agents and Chemotherapy. Available online: https:\/\/journals.asm.org\/doi\/full\/10.1128\/AAC.01051-06."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bsheal.2020.04.004","article-title":"Advanced researches on the inhibition of influenza virus by Favipiravir and Baloxavir","volume":"2","author":"Fang","year":"2020","journal-title":"Biosaf. Health"},{"key":"ref_69","unstructured":"(2022, June 16). Favipiravir as a Potential Countermeasure against Neglected and Emerging RNA Viruses\u2014ScienceDirect. Available online: https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0166354218300172."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_71","unstructured":"(2022, June 16). Eurosurveillance|Assessing Baloxavir Susceptibility of Influenza Viruses Circulating in the United States during the 2016\/17 and 2017\/18 Seasons. Available online: https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES.2019.24.3.1800666?crawler=true."},{"key":"ref_72","unstructured":"(2022, June 16). Eurosurveillance|Detection of Influenza A(H3N2) Viruses Exhibiting Reduced Susceptibility to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir in Japan. Available online: https:\/\/www.eurosurveillance.org\/content\/10.2807\/1560-7917.ES.2019.24.3.1800698?crawler=true."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1900170","DOI":"10.2807\/1560-7917.ES.2019.24.12.1900170","article-title":"Influenza A(H3N2) virus exhibiting reduced susceptibility to baloxavir due to a polymerase acidic subunit I38T substitution detected from a hospitalised child without prior baloxavir treatment, Japan, January 2019","volume":"24","author":"Takashita","year":"2019","journal-title":"Eurosurveillance"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/AAC.44.1.78-87.2000","article-title":"Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies","volume":"44","author":"Barnett","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1001\/jama.297.13.1435","article-title":"Emergence of Influenza B Viruses with Reduced Sensitivity to Neuraminidase Inhibitors","volume":"297","author":"Hatakeyama","year":"2007","journal-title":"JAMA"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/cid\/cis1220","article-title":"Global assessment of resistance to neuraminidase inhibitors, 2008\u20132011: The Influenza Resistance Information Study (IRIS)","volume":"56","author":"Whitley","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(04)16934-1","article-title":"Resistant influenza A viruses in children treated with oseltamivir: Descriptive study","volume":"364","author":"Kiso","year":"2004","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1086\/318537","article-title":"Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir","volume":"183","author":"Gubareva","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1607.091691","article-title":"Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia","volume":"16","author":"Tramontana","year":"2010","journal-title":"Emerg. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/596311","article-title":"Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children","volume":"48","author":"Stephenson","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1098\/rstb.2001.1002","article-title":"Treatment of influenza with neuraminidase inhibitors: Virological implications","volume":"356","author":"Roberts","year":"2001","journal-title":"Philos. Trans. R. Soc. B Biol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dki018","article-title":"Oseltamivir (Tamiflu\u00ae) and it\u2019s potential for use in the event of an influenza pandemic","volume":"55","author":"Ward","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_83","first-page":"443","article-title":"Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system","volume":"111","author":"Drusano","year":"2018","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2010.07.003","article-title":"Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice","volume":"88","author":"Smee","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Checkmahomed, L., Padey, B., Pizzorno, A., Terrier, O., Rosa-Calatrava, M., Abed, Y., Baz, M., and Boivin, G. (2020). In Vitro Combinations of Baloxavir Acid and Other Inhibitors against Seasonal Influenza A Viruses. Viruses, 12.","DOI":"10.3390\/v12101139"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S1473-3099(21)00469-2","article-title":"Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): A randomised, parallel-group, double-blind, placebo-controlled, superiority trial","volume":"22","author":"Kumar","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jac\/dky462","article-title":"Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection","volume":"74","author":"Fukao","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"105126","DOI":"10.1016\/j.antiviral.2021.105126","article-title":"Baloxavir-oseltamivir combination therapy inhibits the emergence of resistant substitutions in influenza A virus PA gene in a mouse model","volume":"193","author":"Park","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.00933-09","article-title":"Effects of the Combination of Favipiravir (T-705) and Oseltamivir on Influenza A Virus Infections in Mice","volume":"54","author":"Smee","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","article-title":"Comparative Effectiveness of Combined Favipiravir and Oseltamivir Therapy Versus Oseltamivir Monotherapy in Critically Ill Patients with Influenza Virus Infection","volume":"221","author":"Wang","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Park, S., Kim, J.I., Lee, I., Lee, S., Hwang, M.-W., Bae, J.-Y., Heo, J., Kim, D., Jang, S.-I., and Kim, H. (2014). Combination Effects of Peramivir and Favipiravir against Oseltamivir-Resistant 2009 Pandemic Influenza A(H1N1) Infection in Mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101325"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.antiviral.2010.09.020","article-title":"Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model","volume":"88","author":"Bantia","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.antiviral.2012.05.004","article-title":"Prophylactic and therapeutic combination effects of rimantadine and oseltamivir against influenza virus A (H3N2) infection in mice","volume":"95","author":"Simeonova","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1177\/135965350701200302","article-title":"Amantadine-Oseltamivir Combination therapy for H5N1 Influenza Virus Infection in Mice","volume":"12","author":"Ilyushina","year":"2007","journal-title":"Antivir. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e1305","DOI":"10.1371\/journal.pone.0001305","article-title":"A Randomized, Crossover Study to Evaluate the Pharmacokinetics of Amantadine and Oseltamivir Administered Alone and in Combination","volume":"2","author":"Morrison","year":"2007","journal-title":"PLoS ONE"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Nguyen, J.T., Hoopes, J.D., Le, M.H., Smee, D.F., Patick, A.K., Faix, D.J., Blair, P.J., De Jong, M.D., Prichard, M.N., and Went, G.T. (2010). Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009332"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1128\/AAC.00476-09","article-title":"Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In Vitro","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Hoopes, J.D., Driebe, E.M., Kelley, E., Engelthaler, D.M., Keim, P.S., Perelson, A.S., Rong, L., Went, G.T., and Nguyen, J.T. (2011). Triple Combination Antiviral Drug (TCAD) Composed of Amantadine, Oseltamivir, and Ribavirin Impedes the Selection of Drug-Resistant Influenza A Virus. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0029778"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Nguyen, J.T., Smee, D.F., Barnard, D.L., Julander, J.G., Gross, M., De Jong, M.D., and Went, G.T. (2012). Efficacy of Combined Therapy with Amantadine, Oseltamivir, and Ribavirin In Vivo against Susceptible and Amantadine-Resistant Influenza A Viruses. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031006"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1473-3099(16)00095-5","article-title":"Detection and sequencing of Zika virus from amniotic fluid of fetuses with microcephaly in Brazil: A case study","volume":"16","author":"Calvet","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2475","article-title":"Combination Therapy with Amantadine, Oseltamivir and Ribavirin for Influenza a Infection: Safety and Pharmacokinetics","volume":"18","author":"Seo","year":"2013","journal-title":"Antivir. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.chest.2016.11.012","article-title":"Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A (H3N2) infection: An open-label randomized, controlled, phase IIb\/III trial","volume":"151","author":"Hung","year":"2017","journal-title":"Chest"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jmii.2020.08.017","article-title":"Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients","volume":"54","author":"Lee","year":"2021","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.antiviral.2013.03.006","article-title":"Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro","volume":"98","author":"Haasbach","year":"2013","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ajpath.2020.12.013","article-title":"Administration of a CXC Chemokine Receptor 2 (CXCR2) Antagonist, SCH527123, Together with Oseltamivir Suppresses NETosis and Protects Mice from Lethal Influenza and Piglets from Swine-Influenza Infection","volume":"191","author":"Ashar","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Madan, A., Chen, S., Yates, P., Washburn, M.L., Roberts, G., Peat, A.J., Tao, Y., Parry, M.F., Barnum, O., and McClain, M.T. (2019). Efficacy and safety of danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir): A phase 2b, global, randomized study of adults hospitalized with influenza. Open Forum Infectious Diseases, Oxford University Press.","DOI":"10.1093\/ofid\/ofz163"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2017.10.035","article-title":"Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir","volume":"818","author":"Kirkpatrick","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jmii.2015.08.016","article-title":"Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus","volume":"50","author":"Huang","year":"2017","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.biopha.2017.12.014","article-title":"Combined efficacy of oseltamivir, isoprenaline and ellagic acid in influenza A (H3N2)-infected mice","volume":"98","author":"Pavlova","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.03947-14","article-title":"Synergistic Effect of Nitazoxanide with Neuraminidase Inhibitors against Influenza A Viruses In Vitro","volume":"59","author":"Belardo","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"104751","DOI":"10.1016\/j.antiviral.2020.104751","article-title":"Prophylaxis of ferrets with nitazoxanide and oseltamivir combinations are more effective at reducing the impact of influenza a virus infection compared to oseltamivir monotherapy","volume":"176","author":"Mifsud","year":"2020","journal-title":"Antivir. Res."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/1\/183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:03:18Z","timestamp":1760119398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/11\/1\/183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["microorganisms11010183"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms11010183","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}